BRAF and chronic myelogenous leukemia, BCR-ABL1 positive: There have been significant advances regarding cancer treatments as of late, including but not limited to earlier detection of primary tumors, increased availability and accessibility of genomic testing; increased utilization of more novel genomic and immunotherapeutic agents (e.g., use of imatinib in chronic myeloid leukemia and use of BRAF inhibitors in melanoma).